An overview of adjuvant formulations and delivery systems

APMIS

Volumn 122, Issue 4, 2014, Pages 257-267

  García, Alexis ^a   De Sanctis, Juan B ^a  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

Adjuvants; Aluminium salts; Cytokines; Delivery system; Immune stimulating complexes (ISCOMS); Liposomes; Nanoparticles; Oil emulsions; Saponin; Toll like receptors; Vaccines

Indexed keywords

ALUMINUM HYDROXIDE; ALUMINUM PHOSPHATE; ALUMINUM POTASSIUM SULFATE; ALUMINUM SALT; CYTOKINE; DECAVAC; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS TOXOID; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; ISCOM; LIPOSOME; MIFAMURTIDE; NANOPARTICLE; PNEUMOCOCCUS VACCINE; QS 21; RECOMBINANT HEPATITIS B VACCINE; SAPONIN; SAPONIN DERIVATIVE; TENIVAC; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VACCINE; WART VIRUS VACCINE; WATER OIL CREAM;

ADJUVANT THERAPY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CELL ACTIVATION; CELLULAR IMMUNITY; CROSS PRESENTATION; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; EMULSION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; LIPOSOMAL DELIVERY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; VACCINATION;

ADJUVANTS; ALUMINIUM SALTS; CYTOKINES; DELIVERY SYSTEM; IMMUNE-STIMULATING COMPLEXES (ISCOMS); LIPOSOMES; NANOPARTICLES; OIL EMULSIONS; SAPONIN; TOLL-LIKE RECEPTORS; VACCINES;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM COMPOUNDS; ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; CYTOKINES; DRUG DELIVERY SYSTEMS; EMULSIONS; HUMANS; ISCOMS; LIGANDS; LIPOSOMES; NANOPARTICLES; SAPONINS; TOLL-LIKE RECEPTORS; VACCINES;

EID: 84895506447     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12143     Document Type: Review

References (75)

1. Ramon G. Diphtheria toxin and anatoxin. Ann Inst Pasteur 1924;38:1-100.
2. McElrath MJ. Selection of potent immunological adjuvants for vaccine construction. Semin Cancer Biol 1995;6:375-85.
3. Dey AK, Srivastava IK. Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens. Expert Rev Vaccines 2011;10:227-51.
4. Douce G, Turcotte C, Cropley I, Roberts M, Pizza M, Domenghini M, et al. Mutants of Escherichia coli heat-labile toxin lacking ADP ribosyl-transferase activity act as non-toxic mucosal adjuvants. Proc Natl Acad Sci USA 1995;92: 1644-8.
5. Chadwic S, Kriegel C, Amiji M. Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev 2010;62:394-407.
6. Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 2008;60:915-28.
7. Sesardic D, Dobbelaer R. European union regulatory developments for new vaccine adjuvants and delivery systems. Vaccine 2004; 22:2452-6.
8. Hem SL, Hogen EH. Aluminium-containing adjuvants: properties, formulation and use. In: Singh M editor. Vaccine Adjuvants and Delivery Systems. Hoboken, NJ: John Wiley & Sons, 2007: 81-114.
9. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nature Immunol 2008;9:847-56.
10. Kool M, Soullié T, van Nimwegen M, Muskens F, Jung S, Hoogsteden HC, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008;205:869-82.
11. Exley C, Siesjö P, Eriksson H. The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol 2010;31:103-9.
12. Podda A, Del Giudice G. Mf59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev Vaccines 2003;2: 197-203.
13. Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects. Vaccine 2012;30:3470-7.
14. Garçon N, Vaughn DW, Didierlaurent AM. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 2012;11:349-66.
15. Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011;29:2461-73.
16. Wijnans L, Lecomte C, de Vries C, Weibel D, Sammon C, Hviid A, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A (H1N1) pdm09 pandemic and vaccination campaigns. Vaccine 2013;31: 1246-54.
17. Bangham AD, Horne RW, Glauert AM. Action of saponins on biological membranes. Nature 1962;196:952-5.
18. Chea EK, Fernández-Tejada A, Damani P, Adams MM, Gardner JR, Livingston PO, et al. Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probes. J Am Chem Soc 2012;134:13448-57.
19. Adams MM, Damani P, Perl NR, Won A, Hong F, Livingston PO, et al. Design and synthesis of potent Quillaja saponin vaccine adjuvants. J Am Chem Soc 2010;132:1939-45.
20. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003;21:335-76.
21. Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines 2009;8: 1663-79.
22. Thoelen S, Van Damme P, Mathei C, Leroux-Roels G, Desombere I, Safary A, et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 1998;16:708-14.
23. Messina JP, Gilkeson GS, Pisetsky DS. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. J Immunol 1991;147: 1759-64.
24. Thomas LJ, Hammond RA, Forsberg EM, Geoghegan-Barek KM, Karalius BH, Marsh HC Jr, et al. Co-administration of a CpG adjuvant (VaxImmune, CPG 7909) with CETP vaccines increased immunogenicity in rabbits and mice. Hum Vaccine 2009;5:79-84.
25. Jurk M, Vollmer J. Therapeutic applications of synthetic CpG oligodeoxy nucleotides as TLR9 agonists for immune modulation. Bio Drugs 2007;21:387-401.
26. Moldoveanu Z, Clements ML, Prince SJ, Murphy BR, Mestecky J. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 1995;13:1006-12.
27. Kovarik J, Bozzotti P, Love-Homan L, Pihlgren M, Davis HL, Lambert PH, et al. CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol 1999;162: 1611-7.
28. Mc Cluskie MJ, Davis HL. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 1998;161:4463-6.
29. Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA 1998;95:15553-8.
30. Eastcott JW, Holmberg CJ, Dewhirst FE, Esch TR, Smith DJ, Taubman MA. Oligonucleotide containing CpG motifs enhances immune response to mucosally or systemically administered tetanus toxoid. Vaccine 2001;19: 1636-42.
31. Pali-Schöll I, Szöllösi H, Starkl P, Scheicher B, Stremnitzer C, Hofmeister A, et al. Protamine nanoparticles with CpG-oligodeoxynucleotide prevent an allergen-induced Th2-response in BALB/c mice. Eur J Pharm Biopharm 2013;85:656-64
32. Zhu Q, Egelston C, Gagnon S, Sui Y, Belyakov IM, Klinman DM, et al. Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice. J Clin Invest 2010;120: 609-16.
33. Cheng C, Jain P, Bettahi I, Pal S, Tifrea D, de la Maza LM. A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors. Vaccine 2011;29: 6641-9.
34. Shafique M, Meijerhof T, Wilschut J, De Haan A. Eevaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses. PLoS ONE 2013;8:e61287.
35. Ghose C, Verhagen JM, Chen X, Yu J, Huang Y, Chenesseau O, et al. TLR5-dependent immunogenicity and protective efficacy of a recombinant fusion protein vaccine containing the non-toxic domains of Clostridium difficile toxins A and B and Salmonella typhimurium flagellin in a mouse model of Clostridium difficile disease. Infect Immun 2013;81:2190-6.
36. Offersen R, Melchjorsen J, Paludan SR, Østergaard L, Tolstrup M, Søgaard OS. TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults. Hum Vaccine Immunother 2012;8:1042-7.
37. Freed DC, Towne VM, Casimiro DR, Zhao Q, Fu TM. Evaluating functional antibodies in rhesus monkeys immunized with hepatitis B virus surface antigen vaccine with novel adjuvant formulations. Vaccine 2011;29:9385-90.
38. Tougan T, Aoshi T, Coban C, Katakai Y, Kai C, Yasutomi Y, et al. TLR9 adjuvants enhance immunogenicity and protective efficacy of the SE36/AHG malaria vaccine in nonhuman primate models. Hum Vaccine Immunother 2013;9 (in press).
39. Hedhli D, Dimier-Poisson I, Judge JW, Rosenberg B, Mévélec MN. Protective immunity against Toxoplasma challenge in mice by coadministration of T. gondii antigens and Eimeria profilin-like protein as an adjuvant. Vaccine 2009;27:2274-81.
40. Fujita Y, Taguchi H. Overview and outlook of Toll-like receptor ligand-antigen conjugate vaccines. Ther Deliv 2012;3:749-60.
41. Heath AW. Cytokines as immunological adjuvants. Pharm Biotechnol 1995;6:645-58.
42. Tovey MG, Lallemand C. Adjuvant activity of cytokines. Methods Mol Biol 2010;626:287-309.
43. Lynch JM, Briles DE, Metzger DW. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12. Infect Immun 2003;71: 4780-8.
44. Perera PY, Lichy JH, Waldmann TA, Perera LP. The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use. Microbes Infect 2012;14:247-61.
45. Thompson AL, Staats HF. Cytokines: the future of intranasal vaccine adjuvants. Clin Dev Immunol 2011;2011:289597.
46. Garçon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011;10:471-86.
47. Singh M, Kazzaz J, Ugozzoli M, Baudner B, Pizza M, Giuliani M, et al. MF59 oil-in-water emulsion in combination with a synthetic TLR4 agonist (E6020) is a potent adjuvant for a combination Meningococcus vaccine. Hum Vaccine Immunother 2012;8:486-90.
48. Henriksen-Lacey M, Korsholm KS, Andersen P, Perrie Y, Christensen D. Liposomal vaccine delivery systems. Expert Opin Drug Deliv 2011;8:505-19.
49. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 2003;422:37-44.
50. Watson DS, Endsley AN, Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine 2012;30:2256-72.
51. Christensen D, Korsholm KS, Wood GK, Mohammed A, Bramwell V, Andersen P, et al. Liposomes in adjuvant systems for parenteral delivery of vaccines. In: Jorgensen L, Nielsen HM, editors. Delivery Technologies for Biopharmaceuticals. UK: John Wiley & Sons Ltd; 2009: 357-76.
52. Brewer JM, Pollock KG, Tetley L, Russell DG. Vesicle size influences the trafficking, processing, and presentation of antigens in lipid vesicles. J Immunol 2004;173:6143-50.
53. Christensen D, Korsholm KS, Rosenkrands I, Lindenstrøm T, Andersen P, Agger EM. Cationic liposomes as vaccine adjuvants. Expert Rev Vaccines 2007;6:785-96.
54. Henriksen-Lacey M, Christensen D, Bramwell VW, Lindenstrøm T, Agger EM, Andersen P, et al. Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. J Control Release 2010;145: 102-8.
55. Bhowmick S, Ravindran R, Ali N. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect Immun 2008;76:1003-15.
56. Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, et al. A new intranasal influenza vaccine based on a novel polycationic lipid- ceramidecarbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine 2006;24:3990-4006.
57. Mitchell LA, Joseph A, Kedar E, Barenholz Y, Galun E. Mucosal immunization against hepatitis A: antibody responses are enhanced by co-administration of synthetic oligodeoxynucleotides and a novel cationic lipid. Vaccine 2006;24:5300-10.
58. Morein B, Sundquist B, Höglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984;308: 457-60.
59. Lövgren K, Morein B. The requirement of lipids for the formation of immunostimulating complexes (ISCOMs). Biotechnol Appl Biochem 1988;10:161-72.
60. Saroja CH, Lakshmi PK, Bhaskaran S. Recent trends in vaccine delivery systems: a review. Int J Pharm Investig 2011;1:64-74.
61. Sun HX, Xie Y, Ye YP. ISCOMs and ISCOMATRIX. Vaccine 2009;27:4388-401.
62. Myschik J, Lendemans DG, McBurney WT, Demana PH, Hook S, Rades T. On the preparation, microscopic investigation and application of ISCOMs. Micron 2006;37:724-34.
63. Pandey RS, Dixit VK. Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B. J Drug Target 2010;18:282-9.
64. Duewell P, Kisser U, Heckelsmiller K, Hoves S, Stoitzner P, Koernig S, et al. ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells. J Immunol 2011;187:55-63.
65. Kreuter J. Nanoparticles. In: Swarbrick J, Boylan JC, editors. Encyclopedia of Pharmaceutical Technology. New York, NY: Marcel Dekker, 1994: vol. 10, 165-90.
66. Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol 2013;3:13.
67. Couvreur P, Barratt G, Fattal E, Legrand P, Vauthier C. Nanocapsule technology: a review. Criti Rev Ther Drug Carrier Sys 2002;19:99-134.
68. Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods 2006;40:1-9.
69. Jung T, Kamm W, Breitenbach A, Hungerer K-D, Hundt E, Kissel T. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-polygraft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm Res 2001;18: 352-60.
70. Chen YS, Hung YC, Lin WH, Huang GS. Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide. Nanotechnology 2010;21:19510.
71. Joshi VB, Geary SM, Salem AK. Biodegradable particles as vaccine delivery systems: size matters. AAPS J 2013;15:85-94.
72. Singla AK, Chawla M. Chitosan: some pharmaceutical and biological aspects-an update. J Pharm Pharmacol 2001;53:1047-67.
73. Ranaldi G, Marigliano I, Vespignani I, Perozzi G, Sambuy Y. The effect of chitosan and other polycations on tight junction permeability in the human intestinal Caco-2 cell line. J Nutrit Biochem 2002;13:157-67.
74. Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Controlled Rel 2001;70:399-421.
75. Oliveira CR, Rezende CM, Silva MR, Pêgo AP, Borges O, Goes AM. A new strategy based on SmRho protein loaded chitosan nanoparticles as a candidate oral vaccine against schistosomiasis. PLoS Negl Trop Dis 2012;6:1-13.